Literature DB >> 27652506

Systemic lupus erythematosus: Epratuzumab not effective in phase III trials.

Sarah Onuora.   

Abstract

Entities:  

Year:  2016        PMID： 27652506     DOI： 10.1038/nrrheum.2016.165

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.

Authors:  Megan E B Clowse; Daniel J Wallace; Richard A Furie; Michelle A Petri; Marilyn C Pike; Piotr Leszczyński; C Michael Neuwelt; Kathryn Hobbs; Mauro Keiserman; Liliana Duca; Kenneth C Kalunian; Catrinel Galateanu; Sabine Bongardt; Christian Stach; Carolyn Beaudot; Brian Kilgallen; Caroline Gordon
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995
  1 in total
  1 in total

Review 1.  Peripheral B Cell Subsets in Autoimmune Diseases: Clinical Implications and Effects of B Cell-Targeted Therapies.

Authors:  Wanlin Jin; Zhaohui Luo; Huan Yang
Journal:  J Immunol Res       Date:  2020-03-23       Impact factor: 4.818
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.